ASOP’s ‘Buy Safe Rx’ campaign guards against rogue online pharmacies
WASHINGTON – This week the Alliance for Safe Online Pharmacies is launching “Buy Safe Rx”, a new campaign to educate consumers about the potentially life-threatening health and financial risks associated with buying prescription medicines online.
In a new report issued in April by the National Association of Boards of Pharmacy, an ASOP Global observer, NABP reviewed nearly 11,000 Internet drug outlets, finding that 96.2% of the sites reviewed operate out of compliance with U.S. pharmacy laws and practice standards. The report also found that approximately 88.3% of NABP’s "Not Recommended" sites are selling prescription drugs without requiring a valid prescription. In addition, approximately 62% do not provide a valid address, and nearly 50% offer drugs that are either foreign, or not approved by the U.S. Food and Drug Administration. Further, of the 10,521 “Not Recommended” sites, 91% can be traced to affiliate networks of rogue Internet drug outlets.
It is estimated that between 100,000 and 700,000 people die every year from counterfeit drugs bought online which are often manufactured in unsafe conditions; contain no active ingredients; and/or contain dangerous substances including floor wax, mercury, concrete, chalk, boric acid, road tar, paint, anti-freeze and other poisons.
Since it was founded in 2009, ASOP Global has been dedicated to addressing the growing public health threat of illegal online drug sellers through strategic efforts around the world, concentrating its activities in research, education, Internet commerce company voluntary actions, and policy and advocacy. Protecting patient safety globally and ensuring patients access to safe, approved medicine through legitimate law-abiding pharmacies is a critical public health issue and top priority for ASOP. The organization works with policymakers, non-profits and domestic and international organizations to help educate consumers and advocate for effective means to protect consumers from the dangerous – and often fatal – risks posed by illegal online drug sellers.
Edward Smith to lead sales operations at Camber
BY DSN STAFF
PISCATAWAY, N.J. — Camber Pharmaceuticals on Wednesday announced that Edward Smith will join the company’s management team as director of sales operations.
Smith brings more than 20 years of supply chain experience to Camber, with the last 15 years being spent in the healthcare industry. His most recent position was VP of contracting for a group purchasing organization. Before that, Smith was director of purchasing at Anda and manager of product management at Henry Schein.
“I feel very fortunate to be able to add such an experienced and high quality individual to our organization” said Kon Ostaficiuk, president of Camber Pharmaceuticals. “Ed will help us continue to grow and fill an integral role in taking Camber to the next level as a premier generics supplier”.
Smith received his MBA from Dowling College in Oakdale, N.Y., and a bachelor of science degree from Widener University in Chester, Pa.
GDUFA up for review, agency says
SILVER SPRING, Md. – The Food and Drug Administration recently announced it will be hosting a public meeting seeking input on the reauthorization of the Generic Drug User Fee Amendments on June 15 here.
According to the agency, the legislative authority for GDUFA expires at the end of September 2017. At that time, new legislation will be required for FDA to continue to collect generic drug user fees for future fiscal years.
FDA is inviting the public to comment on the GDUFA program and provide suggestions regarding the features FDA should propose for the next GDUFA program, especially the assessment of the overall performance of the GDUFA program to date, and aspects of GDUFA that should be retained, changed or discontinued to further strengthen and improve the program.
Loading Post Please Wait...